GEODIS' David Frouin explains why securing the lane outranks sustainability and why full corridor models are the cold chain trend to watch.
|Articles|August 29, 2014
- Pharmaceutical Commerce - September/October 2014
2014 Cold Chain Directory
Our annual compilation of key vendors and service providers in this vital component of pharmaceutical distribution, together with a preview of the IQPC Cold Chain Forum and more late-breaking news
Advertisement
Articles in this issue
about 12 years ago
A conversation with Seyed Mortazavi, IMS Healthabout 12 years ago
PBM formulary exclusion lists continue to growabout 12 years ago
Catalent goes public in a successful IPOabout 12 years ago
EvaluatePharma forecast: 2020 global pharma sales of $1.107 trillionabout 12 years ago
Agency rides the rare-disease waveabout 12 years ago
Legal uncertainties in the DSCSAabout 12 years ago
Is tech running you? Four ways to retake controlAdvertisement
Related to this article
At LogiPharma USA 2026, Cold Chain Technologies' Vijay Paliwal discusses reusable shippers, PCM innovation and AI's role in cold chain risk.
CSafe's Aaron Mantia explains how lane, temperature range, duration and product cost shape thermal protection choices for bulk air cargo.
At LogiPharma USA 2026, Swisslog's Garrett Freeman explains how automation cuts human touches, enforces quarantine and consolidates cold storage.
PAXAFE's Mark Talens explains why real-time visibility starts with process redesign and how it speeds cold chain disposition decisions.
At LogiPharma USA 2026, Cold Chain Technologies' Anthony "TJ" Rizzo discusses cold chain expertise gaps and how data tools are reshaping the profession.
Zoomlogi's Henry Ames explains how AI agents and digitized SOPs help quality managers decide on quarantine or release after a cold chain excursion.
At LogiPharma USA 2026, Cold Chain Technologies' Vijay Paliwal explains how predictive monitoring and right-sized packaging cut excursion risk and waste.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
What DOL’s Final PBM Rule Means for Rebates and Formularies
2
Large Pharma vs. Emerging Biotech: Two Launch Playbooks
3
Pharma Pulse: GoodRx Opens Employer GLP-1 Channel, Lilly Fends Off Novo Ad Challenge, PCMA Takes Aim at Wholesalers
4
FAQ: How DOL’s PBM Disclosure Rule Reaches Drugmaker Contracts
5